The publication of selected abstracts marks an important milestone for a field that has historically struggled for recognition. Lobular breast cancers account for roughly 10 to 15 percent of all invasive breast cancers, yet they behave in ways that standard diagnostic and treatment frameworks often fail to capture. Unlike ductal carcinomas, lobular tumors typically lack the cell adhesion molecule E-cadherin, which allows cancer cells to grow in single-file patterns rather than forming discrete masses. This growth pattern makes lobular cancers notoriously difficult to detect on mammography and to measure accurately on imaging, meaning many patients are diagnosed at later stages than women with ductal tumors.

The symposium itself has grown from a small gathering of specialists into a biannual international event that draws researchers from across oncology, pathology, radiology, and computational biology. The abstract review committee for the 2026 meeting, which held full responsibility for selecting the presentations featured in the supplement, evaluated submissions spanning the full spectrum of lobular carcinoma research, from molecular mechanisms of metastasis to novel imaging strategies and clinical trial design tailored specifically to lobular biology.

One of the central themes running through lobular carcinoma research is the disease’s distinctive metastatic behavior. While ductal breast cancers most often spread to bone, lung, liver, and brain, lobular carcinomas show a striking predilection for unusual metastatic sites, including the gastrointestinal tract, gynecologic organs, and the leptomeninges. These patterns have historically led to delayed or missed diagnoses of metastatic disease, and several presentations at the symposium addressed improved surveillance strategies and the molecular drivers behind this unusual organ tropism.

Imaging challenges also featured prominently in the meeting program. Because lobular tumors infiltrate tissue diffusely rather than forming well-defined lumps, standard mammography frequently underestimates tumor size, and magnetic resonance imaging has emerged as a critical tool for surgical planning. Research presented at the symposium explored how advanced imaging modalities can improve the accuracy of tumor measurement, reduce the need for repeated surgeries, and help clinicians monitor response to neoadjuvant therapy in a disease where conventional response criteria often fall short.

The publication of the abstract collection was sponsored by the University of California San Francisco and funded through a National Cancer Institute grant, reflecting growing institutional support for lobular-specific research. The National Institutes of Health has historically allocated research funding based on disease prevalence and mortality, and advocates for lobular carcinoma patients have argued that the disease’s distinct biology warrants dedicated research investment rather than being folded into general breast cancer programs. The R13 conference grant mechanism that supported the symposium publication is specifically designed to foster scientific meetings that advance research in defined areas.

Genomic research has been a particular driver of the field’s recent momentum. Lobular carcinomas frequently harbor mutations in the CDH1 gene, which encodes E-cadherin, and they also show characteristic alterations in the PI3K signaling pathway and in the transcription factor FOXA1. These molecular features open potential avenues for targeted therapies, and clinical trials of PI3K inhibitors and endocrine therapy combinations in lobular-specific cohorts have been a recurring focus of recent symposia. The abstracts published from the seventh meeting reflect continued interest in translating these genomic insights into treatment strategies that account for the disease’s unique biology.

Another important dimension of the symposium is its role in building a coordinated international research community. Because lobular carcinoma is less common than ductal disease, individual institutions often lack sufficient patient numbers to run robust studies. Collaborative networks formed through the symposium have enabled multi-institutional clinical trials, shared tissue banking efforts, and harmonized data collection, all of which are essential for advancing a disease that requires larger cohorts to generate statistically meaningful results. The supplement’s collection of abstracts serves as a snapshot of this collaborative enterprise, documenting work from laboratories and clinics around the world.

Patient advocacy has also been woven into the symposium’s evolution. Lobular patients often describe a diagnostic odyssey marked by negative mammograms, vague imaging findings, and a lack of disease-specific information. Advocacy organizations have pushed for greater awareness among clinicians and for research that addresses the questions most relevant to patients, including how to monitor for recurrence, how to manage the anxiety of a disease that is hard to image, and how to counsel women with hereditary CDH1 mutations about their cancer risks. The growing visibility of the symposium reflects this advocacy in action.

As the field moves forward, researchers hope that the momentum generated by meetings like the seventh biannual symposium will translate into meaningful clinical improvements: earlier and more accurate detection, better prediction of metastatic risk, and therapies designed specifically for the molecular vulnerabilities of lobular cancer cells. The published abstracts offer a window into that effort, capturing the questions, methods, and early findings that will shape the next generation of lobular carcinoma research. For a disease that has long been understudied relative to its clinical impact, the sustained growth of this international gathering signals that invasive lobular carcinoma is finally getting the focused scientific attention that patients have long called for.

Subject of Research: Selected research abstracts on invasive lobular carcinoma biology, detection, and treatment presented at the 7th biannual international symposium

Article Title: Selected abstracts from the 7th Biannual International Invasive Lobular Carcinoma Symposium: Oral and Poster Presentations

Article References: Selected abstracts from the 7th Biannual International Invasive Lobular Carcinoma Symposium: Oral and Poster Presentations. (2026). Breast Cancer Research and Treatment, 219(S1), Article 17. https://doi.org/10.1007/s10549-026-08047-8

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08047-8

Keywords: invasive lobular carcinoma, breast cancer, symposium abstracts, E-cadherin, CDH1, metastasis, breast imaging, Breast Cancer Research and Treatment, National Cancer Institute, lobular breast cancer research, clinical trials, molecular biology

The research team, led by Di Liu and Guo Deng of The People’s Hospital of the Qiandongnan Miao and Dong Autonomous Prefecture, together with Hanluo Yang and Qingyu Zhang of Jinping County People’s Hospital, began by asking a basic pharmacological question: how sensitive are bladder cancer cells to trifolirhizin? Using cell counting kit-8 assays on two widely studied human bladder carcinoma cell lines, T24 and UMUC3, they measured the concentration required to kill half of the cells. The answer was strikingly consistent across both lines, with IC50 values of 67.41 micromolar for T24 cells and 72.58 micromolar for UMUC3 cells. Those figures establish trifolirhizin as a genuine cytotoxic agent against these aggressive tumor cells rather than a marginal one, and they provided the dosing foundation for every experiment that followed.

Viability alone, however, tells only part of the story in oncology research. A compound can poison cells without touching the behaviors that actually make cancer dangerous: uncontrolled replication and tissue invasion. To probe these hallmarks, the researchers turned to colony formation assays, which measure the capacity of individual tumor cells to multiply into visible colonies over days and weeks. Trifolirhizin treatment markedly reduced the number of colonies the bladder cancer cells could establish, signaling a direct suppression of long-term proliferative potential. This kind of assay is widely regarded as a stringent test of a drug’s anti-tumor character, because surviving even a brief exposure is not enough; the cells must retain the full machinery for sustained growth, and trifolirhizin appears to compromise exactly that machinery.

Invasion was the next target on the team’s list. Malignant tumors earn their lethal reputation not from where they start but from where they spread, and bladder cancer is no exception. The investigators used transwell migration assays to quantify how many cells could push through a membrane barrier, a standard laboratory proxy for invasive behavior. Trifolirhizin treatment significantly decreased the number of invading cells. Crucially, the molecular correlates of that behavioral shift told a coherent story: levels of vimentin, an intermediate filament protein that supports cellular motility and is a classic marker of epithelial-mesenchymal transition, dropped after treatment, while E-cadherin, an adhesion molecule that helps hold epithelial cells together and restrains migration, increased. In other words, the compound appeared to pull the cells back from a mobile, invasive state toward a more settled, epithelial identity.

Perhaps the most forward-looking dimension of the study concerns immune evasion, the process by which tumors render themselves invisible or hostile to the body’s defensive cells. The researchers found that trifolirhizin-treated bladder cancer cells became more vulnerable to CD8-positive T cell-mediated cytotoxicity, the principal killing mechanism of cellular antitumor immunity. Alongside this, they measured elevated levels of interferon-gamma, a cytokine that serves as both a marker and a driver of an activated antitumor immune response. By quantifying cytokines in the culture environment, the team showed that the compound did not merely make tumor cells more fragile; it also shifted the signaling landscape in ways that favor immune recognition and attack. That dual action, direct toxicity plus immune reactivation, is precisely the profile that modern immunotherapy research seeks to amplify.

With the phenotypic effects established, the study moved to its mechanistic core: the AKT/NF-κB pathway. Protein kinase B, universally abbreviated as AKT, is a kinase that promotes survival and growth in countless cancers, while nuclear factor kappa-B is a transcription factor that switches on genes supporting inflammation, survival, invasion, and immune escape. The two are functionally intertwined, with AKT activity frequently reinforcing NF-κB signaling. Using immunoblotting, the researchers showed that trifolirhizin treatment attenuated the phosphorylation of both proteins, effectively dialing down the pathway’s activity. Because phosphorylation is the molecular switch that activates these signaling proteins, its reduction means the pathway was genuinely silenced, not merely perturbed.

Correlation is not causation, however, and the team designed an elegant validation experiment to close that gap. They co-treated the cells with SC79, a pharmacological activator of AKT that forces the pathway back into gear even in the presence of an upstream inhibitor. The result was decisive. When SC79 was added alongside trifolirhizin, the compound’s effects on proliferation, apoptosis, invasion, and immune escape indicators in T24 cells were substantially reversed. Markers that trifolirhizin had pushed in an antitumor direction drifted back toward their malignant baseline. This rescue experiment provides the strongest form of evidence short of genetic knockout that the AKT/NF-κB axis is not merely one of many targets but the central conduit through which trifolirhizin exerts its anticancer activity in bladder carcinoma cells.

Laboratory dishes are one thing; living tumors are another. To test whether the findings would survive the far more complex environment of an organism, the researchers turned to xenograft models, in which human bladder cancer cells are implanted into mice and allowed to form tumors. Animals treated with trifolirhizin carried a visibly reduced tumor burden compared with untreated controls, confirming that the compound’s cytotoxic and antiproliferative effects translate into slower tumor growth in vivo. Tissue analysis reinforced the cellular findings: hematoxylin and eosin staining, immunohistochemistry, and immunoblotting revealed reduced vimentin expression within the tumors, increased markers of apoptosis, and elevated interferon-gamma levels. Once again, the AKT/NF-κB pathway showed consistently inhibited expression in tumors harvested from trifolirhizin-treated mice, mirroring the in vitro mechanism at the level of intact tissue.

The convergence of these results paints trifolirhizin as a multimodal therapeutic candidate, a phrase the authors themselves use in their conclusion. By suppressing proliferation, blunting invasion, promoting apoptosis, and enhancing immune-mediated killing, all through downregulation of a single druggable signaling pathway, the compound occupies an unusually versatile position for a natural product. Pterocarpan flavonoids of this class have long attracted attention in chemoprevention and anticancer research, but their efficacy and molecular mechanisms in bladder carcinoma had remained unexplored until this study. The work was approved by the ethics committee of The People’s Hospital of the Qiandongnan Miao and Dong Autonomous Prefecture, and the authors declare no competing interests.

Cautious optimism is the appropriate stance. The IC50 values lie in the high micromolar range, and the journey from xenograft mice to human patients involves hurdles of pharmacokinetics, safety, and formulation that no cell culture or animal model can predict. Still, the study’s design, combining functional assays, cytokine quantification, flow cytometry, pathway rescue with a pharmacological activator, and in vivo validation, exemplifies the rigorous architecture that transforms a plant-derived molecule into a credible drug lead. For a disease that continues to challenge urologists with recurrence and immune evasion, trifolirhizin now offers a scientifically grounded reason for excitement, and a clear mechanistic road map for the therapies that may follow it.

The choice of T24 and UMUC3 as experimental platforms deserves brief elaboration, since these cell lines embody distinct molecular subtypes of bladder carcinoma. T24 cells are derived from a transitional cell carcinoma and display a highly aggressive, invasive phenotype, while UMUC3 carries activating mutations in the HRAS oncogene, a lesion that sits squarely upstream of the PI3K/AKT cascade. The fact that trifolirhizin suppressed AKT phosphorylation and produced comparable IC50 values in both lines suggests its activity does not depend on a single driver mutation, a property that would broaden its potential applicability across molecularly diverse tumors.

The immune findings also fit into a larger conceptual shift in oncology. For decades, cytotoxic chemotherapy was viewed as inherently immunosuppressive, but it is now understood that certain agents can provoke immunogenic cell death, releasing tumor antigens and inflammatory signals that recruit cytotoxic T lymphocytes. The observed rise in interferon-gamma and the heightened susceptibility of treated cells to CD8-positive T cell killing are consistent with this paradigm, raising the possibility that trifolirhizin could act synergistically with immune checkpoint inhibitors, though such combinations remain untested in this study.

Methodologically, the use of SC79 as a pathway rescue tool reflects a standard of mechanistic proof increasingly expected in natural product research, where compounds often have many off-target effects. By demonstrating that forced AKT reactivation reverses the drug’s phenotypic effects, the authors substantially narrow the causal interpretation. Nevertheless, the study does not identify the direct molecular target of trifolirhizin upstream of AKT, leaving open whether the compound binds AKT itself, an upstream activator, or some other regulator of the cascade. Future work with target-identification techniques such as affinity pull-down or thermal proteome profiling would help resolve this question and clarify whether the high micromolar potency can be improved through rational chemical optimization of the pterocarpan scaffold.

Subject of Research: The anticancer effects of the natural flavonoid trifolirhizin on bladder carcinoma via modulation of the AKT/NF-κB signaling pathway

Article Title: Trifolirhizin induces apoptosis and suppresses proliferation, invasion and immune evasion in bladder cancer via AKT/NF-κB signaling pathway

Article References: Liu, D., Deng, G., Yang, H., & Zhang, Q. (2026). Trifolirhizin induces apoptosis and suppresses proliferation, invasion and immune evasion in bladder cancer via AKT/NF-κB signaling pathway. BioMedical Engineering OnLine. https://doi.org/10.1186/s12938-026-01613-7

Image Credits: AI Generated

DOI: 10.1186/s12938-026-01613-7

Keywords: bladder cancer, trifolirhizin, apoptosis, AKT/NF-κB pathway, immune evasion, cell proliferation, invasion, vimentin, E-cadherin, CD8-positive T cells, interferon-gamma, xenograft models